Discontinued — last reported Q4 '24
Products & Services · Indefinite-lived intangible assets
Emraclidine — Indefinite-lived intangible assets
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2024
Last reportedQ4 2024
Rolls up toTrademarks
How to read this metric
A stable or increasing balance suggests continued investment and confidence in the asset's long-term potential, while a decrease may indicate either impairment or the transition of assets to amortizable status upon commercialization.
Detailed definition
This metric represents the total carrying value of intangible assets associated with the Emraclidine product line that a...
Peer comparison
Comparable to 'Indefinite-Lived Intangible Assets' or 'IPR&D' balances reported on the balance sheets of other pharmaceutical companies.
Metric ID:
abbv_segment_emraclidine_indefinite_lived_intangible_assetsHistorical Data
1 periods
| Q4 '24 | |
|---|---|
| Value | $2.40B |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's emraclidine — indefinite-lived intangible assets?
- AbbVie (ABBV) reported emraclidine — indefinite-lived intangible assets of $2.40B in Q4 2024.
- What does emraclidine — indefinite-lived intangible assets mean?
- The total book value of non-amortizing intangible assets tied to the Emraclidine product line.